Government · Clinical Trials
National Institutes of Health (NIH)
Registry of publicly and privately funded clinical studies conducted around the world, including psychedelic-related trials.
Visit source01 · Preparing Without Promising
Research
Every responsibly delivered treatment begins with research. Understanding how psychedelic medicines are studied — and how tentative findings become established knowledge — helps distinguish genuine scientific progress from premature enthusiasm.
From Early Signals to Established Evidence
Research into psychedelic medicines has expanded across academic centers, hospitals, and clinical research organizations. Early-phase studies often evaluate safety, tolerability, and preliminary indications of benefit in small, carefully selected participant groups. Later-phase studies test whether those signals hold up in larger, more diverse populations and under stricter conditions.
A single promising trial is not the same as an established treatment. Replication across independent investigators, transparent reporting of adverse events, and honest discussion of study limitations are essential to knowing whether a therapy is truly ready for broader clinical use.
What Well-Designed Research Includes
- Clear participant selection criteria and screening for medical and psychiatric contraindications.
- Standardized preparation, session structure, and integration components.
- Appropriate comparison conditions and, where possible, blinding.
- Systematic collection of outcome measures and adverse-event data.
- Adequate duration of follow-up to observe both benefit and durability.
- Independent review by institutional review boards and, in many cases, regulatory agencies.
Interpreting psychedelic research requires care. Effect sizes reported in small trials can shrink in larger studies. Expectancy effects, unblinding, and participant self-selection can all influence outcomes and are actively discussed in the scientific literature.
Verified Resources
For Further Reading
Selected institutional and governmental sources. External links open in a new tab.
Government · Research Overview
National Institute on Drug Abuse (NIDA)
Federal research agency publishing information on hallucinogens, dissociative drugs, and evolving therapeutic investigations.
Visit sourceGovernment · Investigational Drug Guidance
U.S. Food and Drug Administration (FDA)
Draft guidance on the design of clinical trials evaluating psychedelic drugs for the treatment of medical conditions.
Visit source